DATE:
May 17th, 2016
LOCATION:
Crest Hollow Country Club
8325 Jericho Turnpike
Woodbury, NY 11797
TIME:
6:00 PM - 7:00 PM Registration
7:00 PM - 8:00 PM Dinner
8:00 PM - 9:00 PM Educational Program
Entering A New Era of Anticoagulant Reversal Agents
SPEAKER:Danielle Crotty, Pharm.D., BCPS
Clinical Pharmacy Coordinator, Huntington Hospital
EDUCATIONAL OBJECTIVES:
At the completion of this activity, the participant will be able to:
Pharmacists/Technicians:
1. Compare the mechanism of action, indications, pharmacokinetics, and monitoring of warfarin versus the direct-acting oral anticoagulants (DOACs)
2. Present the clinical trial data leading to FDA approval of idarucizumab (Praxbind) for reversal of the anticoagulant effects of dabigatran and review dosing, administration and safety of this new agent.
3. Describe ongoing studies for the investigational agents andexanet alfa and ciraparantag currently seeking FDA approval for Factor Xa inhibitor reversal.
4. Highlight differences between prothrombin complex concentrates (PCCs)
and review the use of KCentra plus IV Vitamin K for rapid warfarin reversal.
Health-system pharmacists, technicians and pharmacy students. This is a knowledge-based program. Cost: There is no charge for members of the LISHP.
Non-Member charge at door is $50.00, no refund
RSVP by May 13, 2016: electronic responses automatically generate a reply; manual responses call Allison Potar-Raich at 516-580-9206.
PHARMACIST ACCREDITATION STATEMENT
NYSCHP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 1.0 contact hour(s) (0.1 CEUs) of ACPE approved continuing education. In order to receive credit, the participant must provide the CE code given at the event on the survey which will be emailed out after the meeting. Participants must provide this code within 45 days of the event. It will take up to 60 days to be uploaded to MY CPE Monitor.